![Propanedioic acid,[5-[[6-[5-(1,1-dimethylethyl)-2-benzoxazolyl]-2-naphthalenyl]oxy]pentyl]-,disodi…](https://static.cymitquimica.com/cas-image/395154-propanedioic-acid-5-6-5-11-dimethylethyl-2-benzoxazolyl-2-naphthalenyl-oxy-pentyl-disodium-salt.png)
CAS: 654080-03-2 - Propanedioic acid,[5-[[6-[5-(1,1-dimethylethyl)-2-benzoxazolyl]-2-naphthalenyl]oxy]pentyl]-,disodium salt
Formula:C29H31NO6・2Na
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | SK-216 REF: IN-DA01ENIKCAS: 654080-03-2 | 98% | To inquire | Mon 02 Dec 24 |
 | SK-216 REF: TR-S550025CAS: 654080-03-2 | - - - | 152.00 €~480.00 € | Fri 10 Jan 25 |
 | SK-216 REF: 3D-EBB08003CAS: 654080-03-2 | Min. 95% | To inquire | Mon 13 Jan 25 |
 | SK-216 REF: TM-T28788CAS: 654080-03-2 | - - - | 552.00 € | Tue 21 Jan 25 |
Ref: IN-DA01ENIK
| 5mg | 268.00 € | ||
| 10mg | 563.00 € | ||
| 25mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Monday 2 Dec 2024
SK-216
Controlled ProductCAS:654080-03-2
Applications SK-216 is a plasminogen activator inhibitor-1 (PAI-1) that limits tumor progression and angiogenesis, a …
Formula:
C29H29NNa2O6
Color and Shape:
Neat
Molecular weight:
533.52
Ref: TR-S550025
| 1mg | 152.00 € | ||
| 5mg | 480.00 € | ||
| 2500µg | 293.00 € |
Estimated delivery in United States, on Friday 10 Jan 2025
SK-216
CAS:654080-03-2
SK-216 is a drug that inhibits the synthesis of messenger RNA and suppresses angiogenesis. This …
Formula:
C29H29NNa2O6
Purity:
Min. 95%
Molecular weight:
533.5 g/mol
Ref: 3D-EBB08003
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Estimated delivery in United States, on Monday 13 Jan 2025
SK-216
CAS:654080-03-2
SK-216 inhibits PAI-1, reducing angiogenesis, VEGF-induced migration, tube formation, and pulmonary fibrosis in mice.
Formula:
C29H31NNa2O6
Color and Shape:
Solid
Molecular weight:
535.548
Ref: TM-T28788
| 10mg | 552.00 € |
Estimated delivery in United States, on Tuesday 21 Jan 2025
